Tenaya Therapeutics Inc
Research Tenaya Therapeutics Inc (TNYA) on Bullrun: market cap USD 157.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTNYA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 157.19M
- Financial periodQ2 2026
- RevenueUSD 1.11M
- Net income-USD 43.39M
- Free cash flow-USD 3.71M
Valuation Snapshot
latest market cap is USD 157.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 90.60M | -USD 68.88M | n/a | -0.59 | USD 100.55M | USD 10.83M | USD 123.27M |
| FY2024 | USD 0 | -USD 111.13M | -USD 91.53M | n/a | -1.31 | USD 4.32M | USD 13.61M | USD 92.85M |
| FY2023 | n/a | -USD 124.08M | -USD 103.31M | n/a | -1.68 | USD 45.68M | USD 12.42M | USD 139.42M |
| FY2022 | n/a | -USD 123.67M | -USD 125.05M | n/a | -2.76 | USD 95.27M | USD 17.00M | USD 243.38M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 157.19M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 153.90M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 123.76M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 220.68M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 134.28M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 782.47M | n/a | n/a | n/a |
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tenaya Therapeutics Inc's market cap?
Tenaya Therapeutics Inc's market capitalization is USD 157.19M.
What does Tenaya Therapeutics Inc do?
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.